Momordica charantia Extracts in Selected Media:Screening of Phytochemical Content and In vitro Evaluation of Anti-Diabetic Properties
Keywords:Momordica Charantia, α, -Amylase Activity, A-Glucosidase Activity, Phytochemical Properties, Anti-Diabetic Properties.
AbstractDiabetes mellitus is a multifunctional disorder which is increasing rapidly in most parts of the world. It has been estimated that up to one third of patients with diabetes mellitus use some form of complementary and alternative medicine. One plant that has received the most attention for its anti-diabetic properties is Momordica charantia commonly referred to as bitter gourd. In this study, bitter gourd was extracted in various media i.e. ethanol, water, citric acid, sodium carbonate and sodium chloride. The samples were evaluated for their in-vitro ability to inhibit Î±-amylase and Î±-glucosidase enzymes activity. Ethanol extract was observed to have maximum inhibition against these enzymes. The IC50 values recorded for inhibition of Î±-amylase activity were 81.34, 87.56, 83.89, 97.71 and 83.12 Î¼g/ml respectively for crude extracts of ethanol, water, citric acid, Na2CO3 and NaCl. Similarly, the ability of extracts to inhibit Î±-glucosidase was reflected in the result pattern ethanol<Na2CO3<NaCl<aqueous<citric acid (i.e. 72.81<75.66<80.15<81.22<83.85 Î¼g/ml). Therefore, ethanol extract has potential applications in developing drug therapy for the treatment of diabetes using bitter gourd.
James, D.C.S. and Lessen, R. Position of the American Dietetic Association: promoting and supporting breastfeeding, J. Am. Diet. Asso., 2009, 109, 1926-1942.
Abi-Chahin, T.C., Hausen. M.D.A., Mansano-Marques, C.M. and Halfoun, V.L.R.D.C. Microvascular reactivity in type 1 diabetic, Arquivos Brasileiros de Endocrinologia eMetabologia. 2009, 53, 741-746.
La Selva, M., Beltramo, E., Passera, P., Porta, M. and Molinatti, G.M. The role of endothelium in the pathogenesis in diabetic micro angiopathy. Acta Diabetologica, 1993, 30, 190-200.
Wild, S., Roglic, G., Green, A., Sicree, R. and King, H. Global prevalence of diabetes, Estimates for the year 2000 and projections for 2030. Diabetes Care, 2004, 27, 1047-1053.
Fonseca, V., Rosenstock, J., Patwardhan, R. and Salzman, A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA, 2000, 283, 1695-1702.
Murugesh, S. and Dhandayuthapani, M. Brief overview of Diabetes. Int. J. Pharm. Pharmaceuti. Sci., 2011, 3, 22-27.
Dey, L., Anoja, S.A. and Yuan, C.S. Alternative therapies for type 2 diabetes. Alternative Med. Rev, 2002, 7, 45-58.
Joseph, B. and Jini, E. Anti-diabetic effects of Momordica charantia (bitter melon) and its medicinal potency. Asian Pac. J. Tropical Dis., 2013, 3, 93-102
Harborne, J.B. Phytochemistry, 1993, Academic press, London, 89-131.
Malik, C.P. and Singh, M.B. Plant enzymology and Histoenzymology, Kalyani publishers, New Delhi, 1980, 278.
Vishnu, K.M. and Murugesan, S. Biogenic silver nanoparticles by Halymenia poryphyroides and its in vitro anti-diabetic efficacy. J. Chem. Pharmaceut. Res., 2013, 5, 1001-1008.
Supraja, P. and Usha, R. Antibacterial and phytochemical screening from leaf and fruit extracts of Momordica charantia. Int. J. Pharm. Bio. Sci., 2013, 4, 787-793.
Patel, D., Kumar, R., Laloo, D. and Hemalatha, S. Diabetes mellitus: an overview on its pharmacological aspects and reported medicinal plants having anti-diabetic activity. Asian Pac. J. Trop. Biomed, 2012, 2, 411-420.
Mccue, P.P. and Shetty, K. Inhibitory effects of rosmarinic acid extracts on porcine pancreatic amylase in-vitro. Asia Pac. J. Clin. Nutr., 2004, 13, 101-106.
Liu, J., Chen, J., Wang, C. and Qui, M. New cucurbitane, triterpenoids and steroidal glycoside from Momordica charantia. Molecules, 2009, 14, 4804-4813.
Harekrishna, B., Dipak, K.B., Gobinda, P.S., Priyanka, S. and Ajay, P.M. Colloids and surfaces A, Physicochem. Eng. Aspects, 2009, 348, 212-216.
Cummings, E., Hundal, H.S., Wackerhage, H., Hope, M., Belle, M. and Adeghate, E. Momordica charantia fruit juice stimulates glucose and amino acid uptakes in L6 myotubes. Mol. Cell Biochem., 2004, 261, 99-104.
Abdollah, M., Zuki, A.B.Z., Goh, Y.M., Rezaeizadeh, A. and Noordin, M.M. The effects of Momordica charantia on the liver in streptozotocin-induced diabetes in neonatal rats. Afr. J. Biotechnol., 2010, 9, 5004-5012.
Nerurkar, P.V., Lee, Y.K. and Nerurkar, V.R. Momordica charantia (bitter melon) inhibits primary human adipocyte differentiation by modulating adipogenic genes. BMC Complement Altern. Med., 2011, 10, 34.
Singh, J., Cumming, E., Manoharan, G., Kalasz, H. and Adeghate, E. Medicinal chemistry of the anti-diabetic effects of Momordica Charantia: active constituents and modes of actions. Open Med. Chem. J., 2011, 5, 70-77.
Shibib, B.A., Khan, L.A. and Rahman, R. Hypoglycaemic activity enzymes glucose-6phosphatase and fructose-1, 6-bisphosphatase and elevation of both liver and red-cell shunt enzyme glucose-6-phosphate dehydrogenase. Biochem. J., 1993, 292, 267-270.
Gadang, V., Gilbert, W., Hettiararchy, N., Horax, R., Katwa, L. and Devareddy, L. Dietary bitter melon seed increases peroxisome proliferator-activated receptor-γ gene expression in adipose tissue, down-regulates the nuclear factor-κ B expression, and alleviates the symptoms associated with metabolic syndrome. J. Med. Fd., 2011, 14, 86-93.
How to Cite
All the articles published in IJND are distributed under a creative commons license. The journal allows the author(s) to hold the copyright of their work (all usages allowed except for commercial purpose).
Please contact us at firstname.lastname@example.org for permissions related to commercial use of the article(s).